Lead Product(s) : 177-Lu RAD202
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Details : 177Lu-RAD202 is an HER2 inhibitor, antibody radiopharmaceutical candiidate, which is being evaluated for the treatment of HER2-expressing solid tumors.
Product Name : 177Lu-RAD202
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : 177-Lu RAD202
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clearance of Amplia's IND for Pancreatic Cancer Trial in US
Details : AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CHM 2101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHM 2101 is a 3rd generation, novel CDH17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including colorectal cancer, gastric cancer and neuroendocrine tumor...
Product Name : CHM 2101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 31, 2023
Lead Product(s) : CHM 2101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RAD204
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RAD Receives Approval for Phase 1 Therapeutic Study of PDL1-nanobody in Non-Small Cell Lung Cancer
Details : RAD204, which targets PDL1-positive NSCLC, which used technology underpinning the trial is Radiopharm’s proprietary nanobody from its NanoMab platform.
Product Name : RAD204
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 10, 2023
Lead Product(s) : RAD204
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CNA3103 is a LGR5 targeted CAR-T cells have potential to be developed as a novel immunotherapy to kill ovarian cancer cells and to reduce ovarian cancer tumor.
Product Name : CNA3103
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CF33-CD19,Blinatumomab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears Imugene IND To Commence onCARlytics First-In-Class Clinical Study
Details : onCARlytics (CF33-CD19, HOV4) is a live, attenuated oncolytic orthopox (vaccinia) virus engineered to encode a truncated human CD19 transgene, resulting in expression of de novo CD19 at the tumour cell surface before virus-mediated tumour cell lysis.
Product Name : onCARlytics
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 19, 2023
Lead Product(s) : CF33-CD19,Blinatumomab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CTH-004
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Shunxi Holding Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cartherics Grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China
Details : The agreement provides Shunxi a licence to develop, manufacture and commercialise CTH-004, for the treatment of multiple solid tumours including ovarian cancer in Greater China, as well as an option to negotiate rights to other CAR-T products that incorp...
Product Name : CTH-004
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 28, 2023
Lead Product(s) : CTH-004
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Shunxi Holding Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CNA3103 CAR-T cell targets LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. CNA3103 have shown promising results with complete tumor regression and no tumor recurrence following a single admin...
Product Name : CNA3103
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eftilagimod Alpha,Avelumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMP321 (eftilagimod alpha) is a soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. It is being investigated in combination with bavencio in metastatic urothelial cancer.
Product Name : Efti
Product Type : Protein
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Eftilagimod Alpha,Avelumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Carina’s CAR-T cell therapy candidate, CNA3103, is targeted at LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers.
Product Name : CNA3103
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable